Treating patients with HRMM: the importance of achieving deep and sustained remission
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2024-10-10
Просмотров: 45
Описание:
Joseph Mikhael, MD, MeD, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ & International Myeloma Foundation, Studio City, CA, discusses the challenges that remain in treating high-risk multiple myeloma (HRMM). When treating patients with high-risk disease, Dr Mikhael emphasizes the importance of using multi-mechanism combination approaches with a longer duration of treatment to achieve measurable residual disease (MRD) negativity and deep remission. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
